TherapeuticsMD is no longer a women's-health operator. It is a one-employee royalty stub sitting on top of a late-2022 license to Mayne Pharma, and the June quarter tests whether that residual claim is collecting cash or merely accruing legal language and a going-concern warning. License revenue of $869 thousand slipped versus the year-ago quarter even as the first half still advanced, which is the wrong direction for a vehicle whose entire equity story is partner sell-through. Reported profitability returned only because sublease and miscellaneous income more than offset an operating loss that still exceeds the royalty line.
The real tension is contractual, not commercial. Mayne is obligated to a twelve-year minimum royalty of $3 million a year, inflation-adjusted, plus an eight percent rate on early United States net sales, yet last year's recognized license line was only $3 million and the first half of this year remains well below a cash run-rate that would clear that floor. A royalty receivable of $16 million on the balance sheet is the present-value residue of that floor. Meanwhile a Delaware lawsuit over net-working-capital true-ups has been steered into the deal's expert process, and Mayne's own countersuit plus indemnification demands sit unaccrued because management says a range of loss cannot be estimated. That is not a quiet royalty collector. It is a residual claim whose largest counterparty is also its largest legal adversary.
Cash rose to $9 million by mid-year and continuing operations produced positive operating cash in the first half, so the going-concern paragraph is not a near-term payroll crisis. It is a statement that an adverse working-capital award, a generic IMVEXXY launch that cuts the rate to two percent, or a Cosette-led change of control at Mayne could exhaust the residual before the contract pays out. The next several quarters resolve whether recognized royalties converge on the contractual floor, whether the expert determination produces cash in or cash out, and whether the strategic-alternatives process produces a buyer for a stub that already trades near book.